ArriVent BioPharma, Inc. AVBP
Set alert
At close
Pre-market · Nov 2, 8:23 AM ET
- YTD
- -26.09%
- 1 year
- -19.49%
- Open
- 15.87
- Prev close
- 14.87
- Mkt cap
- 733.21M
- Vol
- 1.19M
- Avg vol
- 1.19M
- EPS
- -3.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.33
- High
- 16.15
- Forward P/E
- -5.64
- Beta
- 1.35
- Short ratio
- 13.52
- Inst. own
- 100.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 26.34
- 200-d avg
- 27.09
- 1y target
- 22.30
5D chart
Signals (122)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 4:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:40 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:05 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:00 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:50 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:20 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| RSI: Overbought | Oct 28, 11:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 5 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 6 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 6 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
News
5 days ago newsfilecorp.com
Arrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP Investments
New York, New York--(Newsfile Corp. - October 28, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Arrivent BioPharma ("Arrivent" or the "Company") (NASDAQ: AVBP)…
-
6 days ago benzinga.com
Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.
6 days ago marketbeat.com
ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
ArriVent BioPharma NASDAQ: AVBP presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in heavily pretreated metastatic colorectal cancer patients during a virtual…
6 days ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
1 week ago benzinga.com
Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.
1 week ago globenewswire.com
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of…
-
1 week ago benzinga.com
ArriVent BioPharma To Present Initial Safety, Efficacy Results Of Its Phase 1 Trial Of CDH17-Targeted ADC ARR-217 In Participants With Gastrointestinal Cancers At ESMO Congress 2026
ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced…
1 week ago globenewswire.com
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of…
1 week ago businesswire.com
ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop
NEW YORK--(BUSINESS WIRE)---- $AVBP #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Arrivent BioPharma (“Arrivent” or the “Company”)…
-
1 week ago benzinga.com
B. Riley Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29
B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $29.
2 weeks ago globenewswire.com
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of…
-
2 weeks ago benzinga.com
BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target
BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.
2 weeks ago globenewswire.com
ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma (“Arrivent” or the “Company”) (NASDAQ: AVBP). The…
2 weeks ago prnewswire.com
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky
ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential…
-
2 weeks ago benzinga.com
ArriVent BioPharma Doses First Patient In Phase 1 Trial Of Dual-Target ADC ARR-002 For Ovarian And Endometrial Cancer
ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced…
2 weeks ago globenewswire.com
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of…
-
3 weeks ago benzinga.com
Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.
-
3 weeks ago benzinga.com
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.
3 weeks ago gurufocus.com
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
3 weeks ago businesswire.com
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $AVBP--AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law.
-
3 weeks ago benzinga.com
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.
3 weeks ago prnewswire.com
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma
/PRNewswire/ -- Before the opening bell today, ArriVent BioPharma (NASDAQ: AVBP) shares were already down 56.7% in premarket trading after the Company
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18
Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.
3 weeks ago benzinga.com
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led gainers with a 16.3% jump on strong results.
-
3 weeks ago benzinga.com
Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.
-
3 weeks ago benzinga.com
BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29
BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.
3 weeks ago prnewswire.com
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock…
3 weeks ago benzinga.com
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data.
3 weeks ago benzinga.com
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low
ArriVent BioPharma announced its Phase 3 lung cancer trial for firmonertinib missed the primary endpoint but showed secondary benefits.
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday's regular session. The company's market cap stands at $6.9 million. Option Care Health (NASDAQ:OPCH)…
3 weeks ago benzinga.com
Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings
U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
3 weeks ago defenseworld.net
ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month Low – What’s Next?
ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) reached a new 52-week low during trading on Tuesday. The company traded as low as $11.66 and last traded at $12.00, with a volume of 1687237…
3 weeks ago benzinga.com
Dow Jumps 200 Points; US Trade Deficit Widens In August
U.S. stocks rose Tuesday, led by Nasdaq and S&P 500, while August’s trade deficit hit $105.6B. Utilities gained; energy and oil fell.
3 weeks ago globenewswire.com
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of…
1 month ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 month ago defenseworld.net
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts
ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One…
2 months ago defenseworld.net
Deutsche Bank AG Acquires Shares of 39,180 ArriVent BioPharma, Inc. $AVBP
Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor…
2 months ago seekingalpha.com
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case
The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming…
2 months ago defenseworld.net
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock,…
2 months ago benzinga.com
Veeva Systems To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR $200, AEP $139, INTU $430, BCSF $13, GEMI $6, VEEV $275.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $47
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $44 to $47.
6 months ago benzinga.com
Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures rise, Vicor Corp shares dip 2.2% in pre-market trading after beating earnings and sales estimates. Other stocks also decline.
1 year ago benzinga.com
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket